Compression of morbidity: revision 1 to 2

Revision 1

Revision 2

categories: ["longevity", "society"]

tags: ["aging", "healthspan", "public health", "disability", "demography", "health policy"]

summary: "The hypothesis that chronic illness can be postponed into a shorter interval before death, so that added years of life are healthy ones."

summary: "The hypothesis that chronic illness can be postponed into a shorter interval before death, so that added years of life are healthy ones."

updated: "2026-07-27"

updated: "2026-10-29"

humanEvidence: "Disability rates in the United States and several European countries fell through the 1980s and 1990s and then stalled, while years lived with diagnosed chronic disease rose; no national population has been shown to compress morbidity."

humanEvidence: "Disability rates in the United States and several European countries fell through the 1980s and 1990s and then stalled, while years lived with diagnosed chronic disease rose; no national population has been shown to compress morbidity."

issues: ["The National Long Term Care Survey disability decline is stated without a source."]

---

}

```

**Compression of morbidity** is the hypothesis that the age at which chronic illness and disability begin can be pushed back faster than the age of death, shortening the period of poor health at the end of life. It was set out by the Stanford physician James F. Fries in 1980 and has shaped how health systems and gerontologists think about the value of longer life ever since.[^fries1980] Whether it has actually occurred in any national population remains disputed.

**Compression of morbidity** is the hypothesis that the age at which chronic illness and disability

begin can be pushed back faster than the age of death, shortening the period of poor health at the

end of life. The Stanford physician James F. Fries set it out in 1980, and it has shaped how health

systems and gerontologists think about the value of longer life ever since.[^fries1980] Whether it

has actually occurred in any national population remains disputed.

## The 1980 hypothesis

Fries argued from two premises. The first was that human lifespan has a natural ceiling — he took roughly 85 years as the average biological limit — so that the survival curve would become increasingly rectangular as premature death was eliminated, with most people dying in a narrow band near that age. The second was that the onset of chronic disease is more modifiable than the age of death, being driven substantially by behavior: smoking, inactivity, diet, and injury.

Fries argued from two premises. The first was that human lifespan has a natural ceiling, which he

put at an average biological limit of roughly 85 years. As premature death was eliminated, the

survival curve would become increasingly rectangular, with most people dying in a narrow band near

that age. The second premise was that the onset of chronic disease is more modifiable than the age

of death, because it is driven substantially by behavior: smoking, inactivity, diet and injury.

If both held, then improving those behaviors would push illness onset rightward while the death age stayed roughly fixed, squeezing morbidity into a shorter terminal interval. The clinical picture Fries described is of a person who remains functional into their eighties and then declines rapidly over months.

If both held, improving those behaviors would push illness onset later while the age of death stayed

roughly fixed, squeezing morbidity into a shorter terminal interval. Fries pictured a person who

remains functional into their eighties and then declines rapidly over months.

The first premise has not held. [[maximum-human-lifespan|Maximum lifespan]] shows no sign of the fixed ceiling Fries assumed, and mean life expectancy in the longest-lived countries has passed 85 for women. This does not by itself refute the hypothesis; it removes the mechanism Fries relied on to keep the death age still while the onset age moved.

The first premise has not held. [[maximum-human-lifespan|Maximum lifespan]] shows no sign of the

fixed ceiling Fries assumed, and mean life expectancy for women in the longest-lived countries has

passed 85. That does not by itself refute the hypothesis, but it removes the mechanism Fries relied

on to keep the age of death still while the age of onset moved.

## Three scenarios

}

```

The expansion thesis predates Fries. Ernest Gruenberg's "failures of success" argument held that medicine had become better at preventing death from chronic disease than at preventing the disease itself, so survival gains would accumulate as years lived in illness.[^gruenberg1977] Kenneth Manton's dynamic-equilibrium model split the difference: prevalence of chronic conditions rises because people survive with them, but average severity falls because progression slows, leaving aggregate function roughly stable.

The expansion thesis predates Fries. Ernest Gruenberg's "failures of success" argument held that

medicine had become better at preventing death from chronic disease than at preventing the disease

itself, so survival gains would accumulate as years lived in illness.[^gruenberg1977] Kenneth

Manton's dynamic-equilibrium model split the difference. The prevalence of chronic conditions rises

because people survive with them, but average severity falls because progression slows, leaving

aggregate function roughly stable.

These are not merely rival predictions. They imply different things about what medicine is doing. Compression implies prevention is working; expansion implies rescue is working and prevention is not.

The three scenarios also imply different things about what medicine is doing. Compression implies

that prevention is working; expansion implies that rescue is working and prevention is not.

## Evidence

The empirical record is mixed and depends heavily on which outcome is measured.

Measures of *disability* — difficulty with activities of daily living, institutionalization, mobility limitation — improved in the United States and several European countries through the 1980s and 1990s. Analyses of the US National Long Term Care Survey found sustained declines in chronic disability among older adults over that period, consistent with compression.

Measures of *disability* (difficulty with activities of daily living, institutionalization, mobility

limitation) improved in the United States and several European countries through the 1980s and

1990s. Analyses of the US National Long Term Care Survey found sustained declines in chronic

disability among older adults over that period, consistent with compression.

Measures of *disease* moved the other way. Studies tracking years of life lived with diagnosed chronic conditions have generally found expansion: as mortality from cardiovascular disease fell, the number of years spent living with cardiovascular disease rose. Crimmins and Beltrán-Sánchez examined both types of outcome in US data and concluded that the period had produced expansion of morbidity rather than compression, with gains in life expectancy accompanied by more years with disease and, on some measures, more years with functional loss.[^crimmins2011]

Measures of *disease* moved the other way. Studies tracking years of life lived with diagnosed

chronic conditions have generally found expansion: as mortality from cardiovascular disease fell,

the number of years spent living with it rose. Crimmins and Beltrán-Sánchez examined both kinds of

outcome in US data and concluded that the period had produced expansion of morbidity rather than

compression. Gains in life expectancy came with more years with disease and, on some measures, more

years with functional loss.[^crimmins2011]

The disability gains also stalled. Rising obesity and diabetes prevalence in cohorts entering old age after 2000 halted and in places reversed the earlier improvement, and self-reported pain and mobility limitation in middle-aged cohorts have worsened in several high-income countries. Whether the widespread treatment of obesity with [[glp-1-receptor-agonists]] changes that trajectory is not yet answerable from population data.

The disability gains also stalled. Rising obesity and diabetes prevalence in cohorts entering old

age after 2000 halted the earlier improvement and in places reversed it, and self-reported pain and

mobility limitation in middle-aged cohorts have worsened in several high-income countries.

Population data cannot yet show whether the widespread treatment of obesity with

[[glp-1-receptor-agonists]] changes that trajectory.

Where compression does appear cleanly is in selected, self-selected groups. A long-running comparison of members of a runners' club with community controls found both lower mortality and a delay in the onset of disability of more than a decade, with disability curves that diverged rather than converging.[^chakravarty2008] It remains the strongest single piece of evidence that [[exercise-and-aging|sustained physical activity]] compresses rather than merely postpones. Cohort studies of religious communities with low rates of smoking and drinking, including the Californian Seventh-day Adventists later folded into the [[blue-zones]] literature, show similar patterns. These groups are not randomly assigned, so the effect is an upper bound on what behavior could achieve, not an estimate of it.

Compression does appear cleanly in selected and self-selected groups. A long-running comparison of

members of a runners' club with community controls found both lower mortality and a delay of more

than a decade in the onset of disability, with disability curves that diverged instead of

converging.[^chakravarty2008] It remains the strongest single piece of evidence that

[[exercise-and-aging|sustained physical activity]] compresses morbidity and does not merely postpone

it. Cohort studies of religious communities with low rates of smoking and drinking, including the

Californian Seventh-day Adventists later folded into the [[blue-zones]] literature, show similar

patterns. These groups are not randomly assigned, so the effect is an upper bound on what behavior

could achieve, not an estimate of it.

> [!debate] The disagreement in one line

> Compression advocates point to declining disability rates in the late twentieth century; critics point out that those declines coincided with rising disease prevalence and have since stopped, and that the runners and Adventists who show the clearest compression differ from the general population in ways no policy can replicate.

> Compression advocates point to declining disability rates in the late twentieth century. Critics

> reply that those declines coincided with rising disease prevalence and have since stopped, and

> that the runners and Adventists who show the clearest compression differ from the general

> population in ways no policy can replicate.

## Why the evidence is hard to read

Four measurement problems recur.

Diagnostic thresholds move. Hypertension, diabetes and chronic kidney disease have all been redefined downward over the period in question, converting healthy people into diseased ones by definition and mechanically producing "expansion".

Diagnostic thresholds move. Hypertension, diabetes and chronic kidney disease have all been

redefined downward over the period in question, turning healthy people into diseased ones by

definition and mechanically producing "expansion".

Self-report drifts. Rising awareness and screening increase reported morbidity independent of any change in underlying health.

Self-report drifts. Rising awareness and screening increase reported morbidity independent of any

change in underlying health.

Disability depends on environment. Better housing, mobility aids and workplace accommodation reduce measured disability without changing the underlying impairment, so the same body can score as disabled in one decade and not the next.

Disability depends on environment. Better housing, mobility aids and workplace accommodation reduce

measured disability without changing the underlying impairment, so the same body can score as

disabled in one decade and not the next.

And period-versus-cohort confusion is endemic. Most published claims compare cross-sections of different birth cohorts at the same age, which conflates aging effects with cohort effects such as childhood nutrition and smoking history.

Period and cohort effects are routinely confused. Most published claims compare cross-sections of

different birth cohorts at the same age, which conflates aging effects with cohort effects such as

childhood nutrition and smoking history.

## Implications

Which scenario obtains determines the fiscal arithmetic of population aging. Under compression, longer lives are cheaper per person because the expensive interval of dependency stays short. Under expansion, each added year of life expectancy carries an added year of care costs, and long-term care rather than acute medicine becomes the binding constraint. Under dynamic equilibrium, costs shift from hospitals to community care without falling. The distinction also reframes the demographic objection discussed under [[overpopulation-and-longevity]]: a population living longer in good function is not the same burden as one living longer in dependency, and the two are routinely conflated.

Which scenario holds determines the fiscal arithmetic of population aging. Under compression, longer

lives cost less per person because the expensive interval of dependency stays short. Under

expansion, each added year of life expectancy brings an added year of care costs, and long-term care

rather than acute medicine becomes the binding constraint. Under dynamic equilibrium, costs move

from hospitals to community care without falling. The distinction also bears on the demographic

objection discussed under [[overpopulation-and-longevity]]: a population living longer in good

function is not the same burden as one living longer in dependency, though the two are routinely

conflated.

The scenarios carry ethical weight as well. A long terminal interval of dependency is the situation that assisted-dying law was written for, and expansion of morbidity enlarges the population facing it — a point taken up in [[right-to-die-and-right-to-live]]. Whether the therapies that might compress morbidity reach the people whose morbidity is longest is a separate question, treated under [[access-and-inequality]]; national statistics agencies that publish both figures generally find a wider gap in healthy life expectancy between the most and least deprived areas than in life expectancy itself.

The scenarios carry ethical weight as well. Assisted-dying law was written for a long terminal

interval of dependency, and expansion of morbidity enlarges the population facing one, a point taken

up in [[right-to-die-and-right-to-live]]. Whether the therapies that might compress morbidity reach

the people whose morbidity lasts longest is a separate question, treated under

[[access-and-inequality]]. National statistics agencies that publish both figures generally find a

wider gap between the most and least deprived areas in healthy life expectancy than in life

expectancy itself.

This is the pivot on which the [[longevity-dividend]] argument turns. The economic case for investing in aging biology assumes compression: that delaying the [[hallmarks-of-aging|underlying processes]] of aging delays disease onset across the board rather than extending survival with disease. The [[geroscience-hypothesis]] makes the same assumption explicit, and it is why geroscience trials favor composite endpoints counting multiple age-related conditions rather than mortality alone, the design [[nir-barzilai]] built into the proposed TAME trial. Interventions such as [[senolytics]] and [[rapamycin]] are evaluated in animals on precisely this criterion — whether function is preserved, not merely whether survival is longer.

The [[longevity-dividend]] argument turns on this question. The economic case for investing in aging

biology assumes compression: that delaying the [[hallmarks-of-aging|underlying processes]] of aging

delays disease onset across the board instead of extending survival with disease. The

[[geroscience-hypothesis]] makes the same assumption explicit. That is why geroscience trials favor

composite endpoints counting multiple age-related conditions over mortality alone, the design

[[nir-barzilai]] built into the proposed TAME trial. In animals, interventions such as

[[senolytics]] and [[rapamycin]] are judged on exactly this criterion: whether they preserve

function, not only whether they lengthen survival.

The counterexample sits in the animal literature: some life-extending manipulations lengthen the frail interval rather than shortening it, an outcome discussed under [[healthspan]]. If human interventions behaved that way, life extension would deliver expansion by design.

The counterexample comes from the animal literature, where some life-extending manipulations

lengthen the frail interval instead of shortening it, an outcome discussed under [[healthspan]]. If

human interventions behaved that way, life extension would produce expansion by design.

## Outlook

Compression remains a policy target more than an observed fact. The strongest version — that morbidity can be squeezed against a fixed wall of natural death — depends on a premise that demographic data have not supported. The weaker and more useful version, that the proportion of life spent in poor health can be reduced, is testable and has not yet been achieved at population scale anywhere.

Compression remains a policy target more than an observed fact. Its strongest version, in which

morbidity is squeezed against a fixed wall of natural death, depends on a premise that demographic

data have not supported. The weaker and more useful version holds that the proportion of life spent

in poor health can be reduced. It is testable, and no population has yet achieved it at scale.

Whether it becomes achievable depends on something Fries did not consider: whether the onset of multiple age-related diseases shares an upstream driver that can be shifted at once. If it does, compression follows more or less automatically. If chronic diseases are largely independent, postponing them one at a time will keep producing what the record so far shows, which is longer lives containing more illness. Settling that question requires [[aging-biomarkers|measures]] the field does not yet have and trials of a length nobody has yet funded.

Whether it becomes achievable depends on a question Fries did not consider: whether the onset of

multiple age-related diseases shares an upstream driver that can be shifted all at once. If it does,

compression follows more or less automatically. If chronic diseases are largely independent,

postponing them one at a time will keep producing what the record shows so far, which is longer

lives containing more illness. Settling the question requires [[aging-biomarkers|measures]] the

field does not yet have and trials longer than any yet funded.

## See also